🇺🇸 FDA

Company profile · Sponsor

MedImmune

EF1613C · EMA pharma EU
Pipeline
9
Drugs
0
Patents
0

Quick answer

MedImmune (EF1613C) is a pharma company. headquartered in EU. listed on EMA. NovaPharmaNews links 9 pipeline programs, 0 drugs, and 0 patents to this profile..

Company facts

Ticker EF1613C
Exchange EMA
Company type pharma
Headquarters EU

Pipeline (9)

Search pipeline →

  1. CAIV-T

    MedImmune

    Influenza

    phase 2 mab completed

    1 trial

  2. Durvalumab + Oleclumab

    MedImmune

    Stage III Non-small Cell Lung Cancer

    phase 2 small molecule completed

    1 trial

  3. MEDI8897

    MedImmune

    Respiratory Syncytial Virus Infections

    phase 2 small molecule completed

    1 trial

  4. MEDI8968 600 mg IV, 300 mg SC

    MedImmune

    Chronic Obstructive Pulmonary Disease

    phase 2 mab completed

    1 trial

  5. MEDI9929

    MedImmune

    Atopic Dermatitis

    phase 2 mab completed

    1 trial

  6. Monalizumab

    MedImmune

    Advanced Solid Tumors

    phase 2 small molecule active

    1 trial

  7. Motavizumab, palivizumab

    MedImmune

    Respiratory Syncytial Virus Infections

    phase 2 mab completed

    1 trial

  8. Placebo

    MedImmune

    Asthma

    phase 2 small molecule completed

    1 trial

  9. Tralokinumab 300 mg, Q2W

    MedImmune

    Asthma

    phase 2 mab completed

    1 trial

Frequently asked questions

What is MedImmune?

MedImmune (EF1613C) is a pharma company. headquartered in EU. listed on EMA. NovaPharmaNews links 9 pipeline programs, 0 drugs, and 0 patents to this profile..

What pipeline programs does MedImmune sponsor?

We track 9 ClinicalTrials.gov-linked programs for MedImmune, including CAIV-T and 8 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does MedImmune company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.